Single Nucleus and Spatial Transcriptomic Analyses of Pulmonary Fibrosis from the “Lung Transplant” and “Lung Tissue” Biorepositories
Demographics (2)
- AGE - Age at time of collection (phv00572501.v1.p1)
- SEX - Biological sex (phv00572496.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00572503.v1.p1)
Respiratory (4)
- DLCO - Diffusing capacity of the lungs for carbon monoxide, expressed as a percentage of expected value (phv00572507.v1.p1)
- SPIROMETRY_FEV1 - Forced expiratory volume in one second, measured by spirometry (phv00572504.v1.p1)
- SPIROMETRY_FVC - Forced vital capacity, measured by spirometry (phv00572505.v1.p1)
- SPIROMETRY_RATIO - Ratio of FEV1 and FVC, expressed as a percentage (phv00572506.v1.p1)
Substance Use (1)
- SMOKING_STATUS - Smoking status (phv00572502.v1.p1)
Other (30)
- ANALYTE_TYPE - Analyte evaluated from the sample (phv00572518.v1.p1)
- ANALYTE_TYPE - Analyte evaluated from the sample (phv00572522.v1.p1)
- ANALYTE_TYPE - Analyte evaluated from the sample (phv00572530.v1.p1)
- BODY_SITE - Body site from which the tissue was collected (phv00572517.v1.p1)
- BODY_SITE - Body site from which sample was collected (phv00572521.v1.p1)
- BODY_SITE - Body site from which the tissue was collected (phv00572529.v1.p1)
- COLLECTION_METHOD - Surgical intervention at time of collection (phv00572510.v1.p1)
- CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body (phv00572495.v1.p1)
- DIAGNOSIS - Diagnosis (phv00572500.v1.p1)
- DIAGNOSIS_CLASS - Disease groupings used for analyses, ILD = interstitial lung disease, IPF = idiopathic pulmonary fibrosis (phv00572508.v1.p1)
- DISEASE_STAGE - Interstitial lung disease stage (phv00572509.v1.p1)
- EGF - Presence or absence of EGF in the culture media during organoid growth (phv00572516.v1.p1)
- EXPERIMENTAL_BATCH - Experimental batch, organoids in the same batch were cultured, processed and sequenced together. Note that this encompasses the B1-B2-B3 information in sample names (phv00572513.v1.p1)
- GROUPING - Analysis group for this sample based on histopathological assessment (phv00572528.v1.p1)
- IS_TUMOR - Tumor status of the sample (phv00572519.v1.p1)
- IS_TUMOR - Tumor status of the sample (phv00572523.v1.p1)
- IS_TUMOR - Tumor status of the sample (phv00572531.v1.p1)
- PROCESSING - Dissociation method and buffer used for nuclei isolation (phv00572525.v1.p1)
- RAW_IMAGE - Name of the corresponding H&E image for this Visium section in the public dataset (phv00572527.v1.p1)
- SAMPLE_ID - Sample ID (phv00572512.v1.p1)
- SAMPLE_ID - Sample ID (phv00572520.v1.p1)
- SAMPLE_ID - Sample ID (phv00572526.v1.p1)
- SAMPLE_ID - Sample ID (phv00572498.v1.p1)
- SB431542 - Presence or absence of SB431542 (TGF inhibitor) in the culture media during organoid growth. Note that this encompasses the SBadd-SBrmv (added/removed) information in sample name (phv00572515.v1.p1)
- SUBJECT_ID - Subject ID (phv00572499.v1.p1)
- SUBJECT_ID - Subject ID (phv00572494.v1.p1)
- SUBJECT_ID - Subject ID (phv00572497.v1.p1)
- TISSUE_LOCATION - Lobe sampled within lung tissue (phv00572524.v1.p1)
- TREATMENT - Cytokines and soluble factors added to the culture of AT2 organoids. Note that this is also captured in sample names. (phv00572514.v1.p1)
- TREATMENT_STATUS - History of treatment for interstitial lung disease (phv00572511.v1.p1)